Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YT8P
|
|||
| Former ID |
DIB004424
|
|||
| Drug Name |
JNJ-38877605
|
|||
| Synonyms |
C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Johnson & Johnson Pharmaceutical Research & Development LLC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H13F2N7
|
|||
| Canonical SMILES |
CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2
|
|||
| InChI |
1S/C19H13F2N7/c1-27-11-13(10-23-27)16-6-7-17-24-25-18(28(17)26-16)19(20,21)14-4-5-15-12(9-14)3-2-8-22-15/h2-11H,1H3
|
|||
| InChIKey |
JRWCBEOAFGHNNU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 943540-75-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:91417
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00651365) A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.. U.S. National Institutes of Health. | |||
| REF 2 | The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.